Cardiovascular Systems — Q4 FY2022 Earnings Presentation
12 slides from Cardiovascular Systems's earnings presentation, Aug 3, 2022
Slide 1: Q4 FY22 Earnings Supplement
©2022 Cardiovascular Systems, Inc. All Rights Reserved. Q4 FY22 Earnings Supplement August 2, 2022
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation r
Slide 3: Q4 FY22 Worldwide Revenues of $62.5 Million
11.2% increase Q/Q and 12.0% decrease Y/Y Q4 FY22 Worldwide Revenues of $62.5 Million Q4 FY22 Revenue Breakdown Worldwide Peripheral $40.7 9.0% Q/Q -14.7% Y/Y Worldwide Coronary $21.8 15.5% Q/Q -6.3% Y/Y Worldwide Peripheral Worldwide Coronary ($ in millions, Q/Q and Y/Y represent Quarter-over-Quart
Slide 4: Q4 FY22: U.S. Peripheral
Q4 FY22: U.S. Peripheral 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue 2 Includes peripheral orbital atherectomy devices, ViperWire, ViperSlide, Exchangeable cartridges, ViperTrack and other 3 Zilient Guidewires, JADE angioplasty balloons, ViperCath
Slide 5: Q4 FY22: U.S. Coronary
Q4 FY22: U.S. Coronary 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue 2 Includes Diamondback, Coronary Guidewire, ViperSlide and other 3 Includes Sapphire angioplasty balloons, Teleport microcatheters and Scoreflex NC balloons Coronary procedure volum
Slide 6: Q4 FY22: International
Q4 FY22: International Double-digit Q/Q and Y/Y revenue growth driven by Japan and EU coronary 6 Revenue increased 14.4% Q/Q and 35.6% Y/Y • International revenue increased to $5.0 million driven by: • Japan, where revenue increased 7.5% Q/Q and 14.2% Y/Y • Europe, where revenue increased 14.5% Q/Q
Slide 7: Q4 FY22 vs. Q3 FY22 and Q4 FY21
Q4 FY22 vs. Q3 FY22 and Q4 FY22 Dollars in thousands 7 Q4 FY22 Quarter/Quarter Change Year/Year Change Worldwide Revenue $62,496 11.2% -12.0% Worldwide Peripheral Revenue $40,729 9.0% -14.7% Worldwide Coronary Revenue $21,767 15.5% -6.3% U.S. Revenue $57,487 10.9% -14.6% U.S. Peripheral Revenue $40,
Slide 8: Q4 FY22: Select Financial Information
Q4 FY22: Select Financial Information Dollars in thousands, except earnings per share and shares outstanding 8 Q4 FY22 Q3 FY22 Q/Q Change Fav (Unfav) Q4 FY21 Y/Y Change Fav (Unfav) Net revenues $62,496 $56,221 $6,275 $70,987 ($8,491) Cost of goods sold 16,269 14,790 (1,479) 20,634 4,365 Gross Margin
Slide 9: FY23: Annual Guidance
FY23: Annual Guidance 9 For the fiscal year ending June 30, 2023, CSI anticipates: Revenue of $255 million to $265 million; Gross profit as a percentage of revenues of 72% to 74%; Net loss in a range of 9% to 11% of revenues; and Adjusted EBITDA near break-even. Research and development expenses wil
Slide 10: Non-GAAP Financial Measures
Non-GAAP Financial Measures 10 CSI uses Adjusted EBITDA as a supplemental measure of performance and believes this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense
Slide 11: Investor Contact
Investor Contact: Jack Nielsen Vice President, Investor Relations & Corporate Communications 651-202-4919 [email protected] CSI®, Diamondback®, Diamondback 360®, ViperWire®, ViperWire Advance®, Wirion®, Zilient®, ViperTrack®, Propel™, ViperCath™ and ViperCross™ are trademarks of Cardiovascular Sy
Slide 12: Cardiovascular Systems, Inc.
CARDIOVASCULAR SYSTEMS, INC. cS. www.csi360.com
Cardiovascular Systems — Q4 FY2022 Earnings Presentation on 6ix